ArticleClinical and experimental medicine2023

Comment on "immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab".

Rujittika Mungmunpuntipantip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.